Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours

Trial Profile

A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Pembrolizumab (Primary) ; Ruxotemitide (Primary)
  • Indications Advanced breast cancer; Cancer; Head and neck cancer; Lymphoma; Malignant melanoma; Sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Lytix Biopharma
  • Most Recent Events

    • 03 Apr 2019 Results (n=27) assessing safety and efficacy of LTX-315 in patients with advanced melanoma presented at the 110th Annual Meeting of the American Association for Cancer Research
    • 03 Apr 2019 Results (n=27) from advanced sarcoma cohort were presented at the 110th Annual Meeting of the American Association for Cancer Research.
    • 21 Nov 2018 Results presented in the Lytix Biopharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top